Abeona Therapeutics Inc. Common Stock
ABEOAbeona Therapeutics Inc. is a clinical-stage biotech company focused on developing gene and cell therapies for rare genetic diseases. The company aims to address serious and life-threatening conditions by utilizing innovative approaches to improve patient outcomes in areas such as immune disorders, neurological diseases, and genetic disorders.
Company News
Abeona Therapeutics Inc. announced the grant of restricted stock equity awards to seven new employees on December 30, 2025, totaling up to 79,584 restricted shares. The awards vest over three years subject to continued employment. The grants were approved under Nasdaq Listing Rule 5635(c)(4) as material inducement to employment.
Abeona Therapeutics saw a significant stock surge of over 25% after reporting strong Q3 earnings and positive updates on Zevaskyn, its gene therapy treatment for Recessive Dystrophic Epidermolysis Bullosa (RDEB), with major insurers now covering the treatment.
The global cancer gene therapy market is projected to grow from $4.52 billion in 2024 to $13.58 billion by 2030, driven by rising cancer incidences, advancements in personalized medicine, and innovative gene therapy technologies like CRISPR and CAR-T solutions.
AscellaHealth has been ranked No. 535 on the Inc. 5000 list of fastest-growing private companies, highlighting its success in the specialty pharmaceutical industry through strategic acquisitions and innovative patient support services.
The report provides detailed insights into the US orphan drug market, highlighting the significant growth opportunity of over $190 billion by 2030. It covers over 1,400 FDA-designated orphan drugs, including their clinical trials, pricing, dosage, and sales data.
